FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003286102> ?p ?o ?g. }

• W2003286102 abstract "The long term outcome of advanced sarcoma patients treated with trabectedin outside of clinical trials and the utility of maintenance treatment has not been reported. Between 2003 and 2008, patients with advanced sarcoma failing doxorubicin could be treated within a compassionate use program (ATU, Temporary Use Authorization) of trabectedin in France using the standard 3-weekly regimen. Data from 181 patients (55%) were collected from 11 centres and analyzed. Trabectedin was given in first, second, third or fourth line in metastatic phase in 6%, 37%, 33% and 23% of patients respectively. With a median follow-up of 6 years, median PFS and OS were 3.6 months and 16.1 months respectively. The median number of cycles was 3 (range 1–19). Best response were partial response (PR, n = 18, 10%), stable disease (SD, n = 69, 39%) and progressive disease (PD, n = 83, 46%), non evaluable (NE, n = 9, 5%). Thirty patients (17%) had to be hospitalized for treatment- related side effects. Independent prognostic factors in multivariate analysis (Cox model) were myxoid LPS and line of trabectedin for PFS, and myxoid LPS and retroperitoneal sarcomas for OS. Patients in PR or SD after 6 cycles continuing treatment had a better PFS (median 5.3 vs 10.5 months, p = 0.001) and OS (median 13.9 vs 33.4 months, p = 0.009) as compared to patients who stopped after 6 cycles. In this compassionate use program, trabectedin yielded similar or better PFS and OS than in clinical trials. Maintenance treatment beyond 6 cycles was associated with an improved survival." @default.
• W2003286102 created "2016-06-24" @default.
• W2003286102 creator A5004048701 @default.
• W2003286102 creator A5004823659 @default.
• W2003286102 creator A5016385181 @default.
• W2003286102 creator A5019624513 @default.
• W2003286102 creator A5027371764 @default.
• W2003286102 creator A5042202815 @default.
• W2003286102 creator A5052190516 @default.
• W2003286102 creator A5052242950 @default.
• W2003286102 creator A5055039513 @default.
• W2003286102 creator A5057293211 @default.
• W2003286102 creator A5060949051 @default.
• W2003286102 creator A5061469135 @default.
• W2003286102 creator A5065856111 @default.
• W2003286102 creator A5073713547 @default.
• W2003286102 creator A5080620486 @default.
• W2003286102 creator A5082347575 @default.
• W2003286102 creator A5085936617 @default.
• W2003286102 creator A5090103193 @default.
• W2003286102 creator A5091721810 @default.
• W2003286102 date "2013-02-06" @default.
• W2003286102 modified "2023-10-16" @default.
• W2003286102 title "Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program" @default.
• W2003286102 cites W1513901790 @default.
• W2003286102 cites W1589920570 @default.
• W2003286102 cites W1903528106 @default.
• W2003286102 cites W1977993734 @default.
• W2003286102 cites W1980723303 @default.
• W2003286102 cites W1987646951 @default.
• W2003286102 cites W2003174619 @default.
• W2003286102 cites W2018169190 @default.
• W2003286102 cites W2047010121 @default.
• W2003286102 cites W2057195209 @default.
• W2003286102 cites W2063654089 @default.
• W2003286102 cites W2107078868 @default.
• W2003286102 cites W2109361235 @default.
• W2003286102 cites W2109801148 @default.
• W2003286102 cites W2115212952 @default.
• W2003286102 cites W2123302336 @default.
• W2003286102 cites W2134281922 @default.
• W2003286102 cites W2138266786 @default.
• W2003286102 cites W2143530174 @default.
• W2003286102 cites W2157585376 @default.
• W2003286102 cites W2157598836 @default.
• W2003286102 cites W2168598691 @default.
• W2003286102 cites W2262986705 @default.
• W2003286102 doi "https://doi.org/10.1186/1471-2407-13-64" @default.
• W2003286102 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3620689" @default.
• W2003286102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23388156" @default.
• W2003286102 hasPublicationYear "2013" @default.
• W2003286102 type Work @default.
• W2003286102 sameAs 2003286102 @default.
• W2003286102 citedByCount "70" @default.
• W2003286102 countsByYear W20032861022013 @default.
• W2003286102 countsByYear W20032861022014 @default.
• W2003286102 countsByYear W20032861022015 @default.
• W2003286102 countsByYear W20032861022016 @default.
• W2003286102 countsByYear W20032861022017 @default.
• W2003286102 countsByYear W20032861022018 @default.
• W2003286102 countsByYear W20032861022019 @default.
• W2003286102 countsByYear W20032861022020 @default.
• W2003286102 countsByYear W20032861022021 @default.
• W2003286102 countsByYear W20032861022022 @default.
• W2003286102 crossrefType "journal-article" @default.
• W2003286102 hasAuthorship W2003286102A5004048701 @default.
• W2003286102 hasAuthorship W2003286102A5004823659 @default.
• W2003286102 hasAuthorship W2003286102A5016385181 @default.
• W2003286102 hasAuthorship W2003286102A5019624513 @default.
• W2003286102 hasAuthorship W2003286102A5027371764 @default.
• W2003286102 hasAuthorship W2003286102A5042202815 @default.
• W2003286102 hasAuthorship W2003286102A5052190516 @default.
• W2003286102 hasAuthorship W2003286102A5052242950 @default.
• W2003286102 hasAuthorship W2003286102A5055039513 @default.
• W2003286102 hasAuthorship W2003286102A5057293211 @default.
• W2003286102 hasAuthorship W2003286102A5060949051 @default.
• W2003286102 hasAuthorship W2003286102A5061469135 @default.
• W2003286102 hasAuthorship W2003286102A5065856111 @default.
• W2003286102 hasAuthorship W2003286102A5073713547 @default.
• W2003286102 hasAuthorship W2003286102A5080620486 @default.
• W2003286102 hasAuthorship W2003286102A5082347575 @default.
• W2003286102 hasAuthorship W2003286102A5085936617 @default.
• W2003286102 hasAuthorship W2003286102A5090103193 @default.
• W2003286102 hasAuthorship W2003286102A5091721810 @default.
• W2003286102 hasBestOaLocation W20032861021 @default.
• W2003286102 hasConcept C126322002 @default.
• W2003286102 hasConcept C141071460 @default.
• W2003286102 hasConcept C142724271 @default.
• W2003286102 hasConcept C143998085 @default.
• W2003286102 hasConcept C2778256501 @default.
• W2003286102 hasConcept C2778629024 @default.
• W2003286102 hasConcept C2780752271 @default.
• W2003286102 hasConcept C2781413609 @default.
• W2003286102 hasConcept C2908902254 @default.
• W2003286102 hasConcept C535046627 @default.
• W2003286102 hasConcept C71924100 @default.
• W2003286102 hasConceptScore W2003286102C126322002 @default.
• W2003286102 hasConceptScore W2003286102C141071460 @default.
• W2003286102 hasConceptScore W2003286102C142724271 @default.
• W2003286102 hasConceptScore W2003286102C143998085 @default.

• next